| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Dipeptidyl peptidase-4 inhibitors and the risk of infection: A systematic review and meta-analysis of cardiovascular outcome trials
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Na Yang, Li-Yun He, Peng Liu, Zi-Yi Li, Yu-Cheng Yang, Fan Ping, Ling-Ling Xu, Wei Li, Hua-Bing Zhang and Yu-Xiu Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National High Level Hospital Clinical Research Funding |
2022-PUMCH-B-015 |
| Beijing Municipal Natural Science Foundation |
No.M22014 |
| CAMS Innovation Fund for Medical Sciences |
No. 2023-I2M-C&T-B-043 and No. 2021-I2M-1-002 |
| National Natural Science Foundation of China |
No. 91846106 |
|
| Corresponding Author |
Hua-Bing Zhang, MD, Chief Doctor, Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing Street, Beijing 100730, China. huabingzhangchn@163.com |
| Key Words |
Dipeptidyl peptidase-4 inhibitors; Type 2 diabetes mellitus; Overall infection; Site-specific infections; Meta-analysis |
| Core Tip |
This meta-analysis revealed no significant correlation between dipeptidyl peptidase-4 (DPP-4) inhibitor usage and the risk of overall, serious, opportunistic, or site-specific infections in patients with type 2 diabetes participating in cardiovascular outcome trials. These findings suggest that DPP-4 inhibitors do not pose a heightened risk of infections compared to other treatments used for these patients. However, further long-term studies and real-world surveillance are warranted to examine the broader implications of DPP-4 inhibitors therapy on infection susceptibility in clinical settings. |
| Publish Date |
2024-05-10 11:51 |
| Citation |
Yang N, He LY, Liu P, Li ZY, Yang YC, Ping F, Xu LL, Li W, Zhang HB, Li YX. Dipeptidyl peptidase-4 inhibitors and the risk of infection: A systematic review and meta-analysis of cardiovascular outcome trials. World J Diabetes 2024; 15(5): 1011-1020 |
| URL |
https://www.wjgnet.com/1948-9358/full/v15/i5/1011.htm |
| DOI |
10.4239/wjd.v15.i5.1011 |
